Archives

  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2018-07
  • br MM or CSR It has been reported

    2022-04-29


    MM or CSR. It has been reported rituximab treatment resulted in a significant clinical improvement in LEMS [26]. One patient in our study gained the status of MM-3 after rituximab treatment with QMG score dropping from 18 to 2 in 6 months.
    In conclusion, patients with SCLC-LEMS tended to take less time to make the diagnosis and have a higher prevalence of ataxia com-paring with NT-LEMS. In SCLC patients, those with LEMS showed a favorable prognosis according to their survival time. Most NT-LEMS showed improvement or obtained CSR/PR/MM after immunosuppressive treatment.
    Funding
    This work was supported by the National key Research and Development Program of China (No. 2016YFC0901504).
    Disclosures
    The authors declare no conflicts of interest.
    Appendix A. Supplementary material
    References
    [1] Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10:1098–107.
    [3] Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, et al. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003;53:21–8.
    [4] Wirtz PW, Nijnuis MG, Sotodeh M, Willems LN, Brahim JJ, Putter H, et al. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 2003;250:698–701. [5] Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel Temozolomide in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467–74.
    [6] Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35–42. 
    [7] Oh SJ, Kurokawa K, Claussen GC, Ryan HFJ. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515–20.
    [15] Burns TM, Russell JA, LaChance DH, Jones HR. Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003;53:270–3.
    [16] Wirtz PW, Sotodeh M, Nijnuis M, Van Doorn PA, Van Engelen BG, Hintzen RQ, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002;73:766–8.
    [17] Abenroth DC, Smith AG, Greenlee JE, Austin SD, Clardy SL. Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population. Muscle Nerve 2017;56:421–6. [18] Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999;353:117–8.
    [19] Wirtz PW, Lang B, Graus F, van den Maagdenberg AM, Saiz A, de Koning GPA, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005;164:161–5.
    [20] Liu X, Jiang T, Li W, Li X, Zhao C, Shi J, et al. Characterization of never-smoking and its association with clinical outcomes in Chinese patients with small-cell lung cancer. Lung Cancer 2018;115:109–15. [21] Cai Q, Luo HL, Gao XC, Xiong CJ, Tong F, Zhang RG, et al. Clinical features and prognostic factors of small cell lung cancer: a osmoregulators retrospective study in 148 patients. J Huazhong Univ Sci Technol Med Sci 2016;36:916–22. [22] Liu S, Guo H, Kong L, Li H, Zhang Y, Zhu H, et al. The prognostic factors in the elderly patients with small cell lung cancer: a retrospective analysis from a single cancer institute. Int J Clin Exp Pathol 2015;8:11033–41. [23] Maddison P, Gozzard P, Grainge MJ, Lang B. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2017;88:1334–9.
    [24] Hulsbrink R, Hashemolhosseini S. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy. Clin Neurophysiol 2014;125:2328–36. [25] Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86:44–8. [26] Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671–3. Original Study